Financial Data and Key Metrics Changes - In H1 2025, revenue increased by 11.2% year-over-year, reaching RMB 3,192 million [4] - The gross profit margin grew by 2.4%, reaching 65.6% [7] - Operating cash flow was significantly decreased, but the company expects it to exceed RMB 1 billion for the year [10][38] - The loss from the same period last year was reduced from RMB 280 million to RMB 98 million [10] Business Line Data and Key Metrics Changes - Cloud subscription revenue grew by 22.1% year-over-year, with an annual recurring revenue (ARR) growth of 80.5% [13] - The contract liability of cloud subscriptions increased by 24.7% [13] - The gross profit margin for cloud subscriptions was 96.2%, a 0.9 percentage point increase compared to last year [13] Market Data and Key Metrics Changes - The company reported that cloud subscription revenue now accounts for over 50% of total revenue, with a significant contribution from the Kinky Cloud and Constellation platforms [16][23] - The net total retention rate for Constellation subscriptions was 108% [15] Company Strategy and Development Direction - The company is adjusting its strategy to seek more opportunities while controlling internal risks, particularly in the context of persistent macroeconomic challenges and the rise of artificial intelligence [3] - The focus is on transforming from a traditional one-time license model to a subscription-based model, emphasizing cloud services and AI integration [21][24] - Future plans include strengthening SaaS offerings and expanding AI capabilities, with a goal for AI revenue to account for 30% of total revenue by 2030 [39][68] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the volatility of the external environment but expressed confidence in achieving profitability and strong cash flow growth in the coming years [12][96] - The company aims for a sustainable margin of around 8% and expects to maintain a high gross profit margin due to the growth of the subscription business [97] Other Important Information - The company has introduced various AI-powered products, receiving positive feedback from clients, particularly for the Gold Key financial report analytics app [48][49] - The company is actively expanding its international presence, with plans to consolidate its foothold in Southeast Asia and the Middle East, and aims for international revenue to reach 5% to 10% of total revenue in the next three to five years [104] Q&A Session Summary Question: What is the trend of demand for large, medium, and small enterprises? - Management noted that large enterprises are integrating their business lines for better supply chain management, while medium-sized enterprises seek faster deployment and lower costs [42][44] Question: What is the pricing model for AI products and customer feedback? - The company received positive responses for AI products launched in May, with large companies interested in pilot testing and mid-sized companies needing full systems [43][46] Question: What is the sustainability of the cloud business transformation? - Management expressed confidence in sustainable growth, with a target for subscription business to increase from 50% to 80-90% of total revenue [70] Question: What are the plans for international business? - The company plans to localize products for different regions and aims to expand into Africa, Europe, and Japan starting in 2026 [77][104] Question: How will team optimization impact project implementation? - Management clarified that team optimization aims to improve efficiency without sacrificing customer experience, with implementation services being outsourced to certified partners [58][60]

Financial Data and Key Metrics Changes - In Q2 2025, the company reported revenue of approximately $1,060 million, reflecting a year-over-year decline of about 3% on both constant currency and reported basis [20][21] - Non-GAAP operating margin was 23.8%, an increase of 160 basis points year-over-year, while non-GAAP EPS was $1.19, growing 9% year-over-year and exceeding guidance [5][28][29] - Non-GAAP gross margin was 69.4%, stable year-over-year, with a favorable product mix contributing to improved performance [27] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was approximately flat year-over-year at $740 million, with high throughput consumables showing over 10% sequential growth [21][22] - The transition to the NovaSeq X platform is progressing, with over 80% of sequencing volumes for research customers already transitioned, and clinical customers at approximately 55% [22] - Sequencing instruments revenue was down approximately 18% year-over-year, primarily due to budget constraints from research customers [24] Market Data and Key Metrics Changes - Clinical markets now account for roughly 60% of total sequencing consumables, driven by comprehensive genomic profiling and sequencing-intensive applications [5][21] - Greater China revenue was $63 million, slightly ahead of expectations but down $12 million from 2024, with ongoing discussions with regulators regarding export restrictions [20][32] Company Strategy and Development Direction - The company aims for high single-digit revenue growth and to expand non-GAAP operating margin to 26% by 2027, focusing on growing the core sequencing business and expanding services [9][31] - The acquisition of Somologic for $350 million is expected to enhance the company's capabilities in proteomics, integrating it into their multiomics strategy [30][12] Management's Comments on Operating Environment and Future Outlook - Management expressed caution for the second half of 2025 due to ongoing funding uncertainties in the U.S. research market, despite raising guidance for total company revenue growth [16][17] - The clinical segment is expected to continue driving growth, with significant opportunities in oncology and genetic disease testing [80] Other Important Information - The company repurchased approximately 4.5 million shares for $380 million, with plans to continue share repurchases throughout the year [29][30] - The company ended the quarter with approximately $1,160 million in cash and equivalents, maintaining a gross leverage of approximately 1.7x [30] Q&A Session Summary Question: Guidance change and its components - The guidance increase was attributed to FX and increased expectations for consumables, while instrumentation expectations were reduced due to research market constraints [40][44] Question: Customer behavior in anticipation of competition - The company focuses on customer engagement and innovation to remain competitive, with ongoing efforts to understand customer needs [48][50] Question: Pull forward in customer orders - No significant pull forward was observed in Q2, with a normal quarter reported; however, increased backlog was noted for future orders [56][57] Question: Clinical customer spending patterns - Clinical customers are expected to continue investing in expanding their portfolios, with a gradual transition to the NovaSeq X platform [78][82] Question: Trajectory of X placements - The company anticipates continued placements of NovaSeq X instruments, with expectations of 50-60 placements per quarter [90]

Financial Data and Key Metrics Changes - The company is focused on achieving high single-digit revenue growth and 500 basis points of margin expansion by 2027, excluding the Greater China region [30][31] - The company has made cost reductions of approximately $100 million this year and beyond to improve its financial position [24][36] Business Line Data and Key Metrics Changes - The clinical segment accounts for approximately 55% of revenue and showed strong growth in Q1, with good placements of the X platform and mid-single-digit growth in consumables [60] - The academic and government end market, which represents about 50% of revenue, has been lowered by 15% in guidance due to funding pressures [42][47] Market Data and Key Metrics Changes - The company has noted that more than 50% of its revenue comes from clinical applications, with less than 50% from academic research, indicating a significant reliance on clinical markets [44] - The company expects the long-term growth rate for the academic market to return to around 6%, but anticipates subdued growth through 2025 due to current uncertainties [46][47] Company Strategy and Development Direction - The company is transitioning to focus on end-to-end workflows and deep insights rather than solely on sequencing, aiming to drive genomics to the next level [26][30] - The strategy emphasizes customer intimacy and operational excellence, with a commitment to innovation and maintaining a competitive edge in the market [17][71] Management's Comments on Operating Environment and Future Outlook - Management acknowledged unexpected challenges in 2025, including being placed on the unreliable entity list by Chinese authorities and NIH funding challenges, but emphasized the importance of controlling what can be controlled [21][22] - The company remains optimistic about growth opportunities in the multiomics space and believes that new product introductions will drive future revenue [34][39] Other Important Information - The company is committed to maintaining a strong presence in China, despite current challenges, and sees potential long-term opportunities in the market [54][56] - The company has launched new technologies, such as Constellation, which are expected to enhance its product offerings and customer engagement [74][90] Q&A Session Summary Question: What are the company's expectations for academic growth? - Management believes that academic growth may return to the expected 6% in the future, but it is uncertain whether this will happen within the next four years [42][46] Question: How does the company plan to address competition in the clinical market? - Management emphasized the importance of innovation and customer reliance on Illumina's solutions, stating that customers recognize the value of their investments in Illumina's technology [62][66] Question: What is the company's stance on the situation in China? - Management stated that while China represents less than 5% of revenue, they are actively working to improve relations and maintain a presence in the market, viewing it as a long-term opportunity [52][54]